- LOGIN
- MemberShip
- 2026-04-13 04:35:24
- Company
- Is there a shortage of chickenpox vaccines?
- by Moon, sung-ho Dec 21, 2021 06:05am
- Contrary to the opinions of the medical community, SK Bio and GC Pharma said, "There is no problem in supplying chickenpox vaccines." The shortage of influenza (flu) vaccines in the second half of this year is causing confusion due to concerns that chickenpox vaccines may also be insufficient. Pharmaceutical and bio companies that produce chickenpox vaccines say there is no problem with supply, but there are already opinions that they should prepare for the shortage of vaccines at medical sites centered on related societies. According to the medical and pharmaceutical industries on the 25th, GC Pharma's "Barycela" is currently available for vaccination. There are 'Vari-L Vaccine' by Boranpharma and Sky Varicella by SK Bioscience. Among them, as the government recently declared "With Corona", there are opinions concerned about the increase in the number of people with infectious diseases such as flu and chickenpox at the medical site. Professor Eom Joong-sik (Infectious Medicine) at Gil Hospital said, "According to related data, infectious medicine doctors believe that the rate of wearing masks has definitely fallen. Considering that the flu and chickenpox are often occurring, the amount of contact is increasing." Accordingly, medical scientists and societies are concerned about the shortage of chickenpox vaccines and are preparing for the possible shortage of vaccines through changes in vaccination guidelines internally. There is a sense of crisis due to the fact that they already experienced a shortage of flu vaccines in the second half of the year. Currently, the government is vaccinating chickenpox vaccines free of charge for infants 12 to 15 months old. A KAPID executive said, "GC Pharma has stopped supplying chickenpox boxes and the launch of a next-generation vaccine, an alternative item, is also being delayed. It was originally scheduled to be released last year, but it was postponed to early this year, but we haven't heard of the release plan yet. As a result, we believe there is a possibility that the launch will be delayed further, he hinted. Another KAPID executive said, "In the case of chickenpox, if there is a shortage of vaccines, we are internally sharing the opinion that new, that is, initial vaccinations should be delayed and patients subject to secondary vaccinations should be vaccinated first." He then said, "It hasn't happened yet, so we're preparing for now." He said, "It would be fortunate if SK Bioscience, which accounts for the largest volume, supplies it normally." Pharmaceutical and bio companies that are supplying chickenpox vaccines to Korea say there is no problem at the moment. They say they are overly concerned at the clinical site. GC Pharma explains that it can supply its new product Barycela in earnest from the second half of this year, replacing Suduvax, which has decided to suspend supply. It is true that the plan to start supply in January this year after obtaining product approval in March last year has been delayed due to problems such as prolonged Corona and delayed NIP registration, but it has entered the normalization stage from the second half of the year. An official from GC Pharma said, "After deciding to stop supplying Suduvax, we will be able to supply Barycela, which was developed as a next-generation vaccine, without any problems. As a result of internal confirmation, we believe that the supply is going well enough." SK Bioscience, which accounts for the largest portion of the domestic chickenpox vaccine supply, is in a position that there will be no problem in supplying vaccines like GC Pharma. An official from SK Bioscience said, "As of the third quarter, Sky Varicella's share among chickenpox vaccines in Korea was 43%," and emphasized, "In the case of flu vaccines, there were some difficulties in producing and supplying chickenpox vaccines."
- Company
- Losartan products are about to be withdrawn from the market
- by Kim, Jin-Gu Dec 20, 2021 06:12am
- With the recovery of Losartan with excessively detected impurities, pharmaceutical companies are considering strategies after recovery measures are completed. Many pharmaceutical companies that did not have a very high market share in the Losartan market are reportedly considering gradually withdrawing from the market after the recovery is completed. It is predicted that the pace of market reorganization will accelerate after the recovery measures are completed. According to the pharmaceutical industry on the 20th, a large Korean pharmaceutical company A is discussing ways to stop selling the product line after the recovery of Losartan is completed. Company A has five Losartan items, and some or all of these products are subject to collection. According to UBIST, a pharmaceutical market research firm, the amount of outpatient prescriptions for company A's five Losartan items last year was more than 7 billion won. It is confirmed that more than 5 billion won was prescribed cumulatively by the third quarter of this year. The pharmaceutical industry interprets the reason why Company A is considering withdrawing the market as to resolve uncertainties. Since NDMA impurities were first discovered in Valsartan in 2018, the pharmaceutical industry has struggled with the impurity crisis every year. In particular, since all impurity incidents occurred in unexpected situations, it was difficult for companies as sales suspension and recovery were repeated after detecting impurities. Moreover, in the case of Company A, it is considered the background of considering withdrawal from the market since it has various ARB drugs such as Telmisartan, Candesartan, Valsartan and and Irbesartan. An official from Company A said, "Nothing has been accurately decided yet. Losartan's prescription performance is not bad, but other ARB-based drugs are larger in terms of the total amount of prescription," he said. The pharmaceutical industry predicts that pharmaceutical companies, including Company A, will withdraw from the market after the recovery of the Losartan hypertension treatment is completed. As of last year, the amount of outpatient prescriptions in the hypertension treatment market, including Losartan, was 320.8 billion won, with two companies, Hanmi and Organon accounting for more than half (53.9%). Hanmi's five types of Losartan recorded 122.4 billion won in prescriptions last year, accounting for 38.1% of the market share. Organon accounts for 15.8%. It was followed by 3.9% per Chong Kun Dang, 3.0% of SK Chemicals, 2.9% of Samik, 2.4% of Kyung Dong, 2.2% of HK inno.N, and 2.0% of Daewoong Bio. In addition, 91 companies are competing for the remaining 27.5%. Most pharmaceutical companies' annual prescriptions are less than 500 million won. The MFDS announced on the 7th that all or some manufacturing number products of 295 items from 98 companies that were detected or feared to exceed the daily intake allowance will be voluntarily recovered. The pharmaceutical industry is in the process of recovering the product.
- Opinion
- [Reporter’s View] Have we secured enough COVID-19 pills?
- by Dec 20, 2021 06:12am
- The world is in preparations to use oral COVID-19 treatments to end the pandemic. Following the UK, Demark became the second country to authorize the use of MSD’s (US Merck’s) ‘molnupiravir,’ with the EU and the US also reviewing approval of the said drug. Pfizer’s oral treatment ‘Paxlovid’ is also under regulatory review. Korea has also joined in the preparations and started the review process for ‘molnupiravir,’ and signed an advance purchase agreement with MSD and Pfizer for 312,000 courses of their treatments (242,000 courses from MSD and 70,000 courses from Pfizer). The authorities also significantly increased the budget for such purchases. Although 36.2 billion won was first allocated for COVID-19 treatments, the National Assembly had passed 192 billion won as reserve funds for additional purchases of such treatments on the 14th. As a result, a total of 228.2 billion won is being invested for oral COVID-19 treatments in Korea. Considering the total purchase volume alone, it may seem that Korea has secured a sufficient amount of oral treatments. However, with the pros and cons of the two treatments taking shape, it is questionable whether the amount and ratio of the two were a wise purchase. The government believes that there is a sufficient supply of oral treatments to prescribe to non-hospitalized COVID-19 patients who will be at high risk of progressing to severe disease. The weekday daily confirmed COVID-19 cases as of December 19th was 6,834 per day, with an average of 755 hospitalizations per day. The drug will be used on COVID-19 patients with comorbidities such as old age, obesity, diabetes, heart condition, etc among the daily 6,079 non-hospitalized cases. Although the molnupiravir that Korea purchased the most is, in theory, effective against all COVID-19 variants, the most recent clinical trial left lingering questions regarding its efficacy against the more recent variants. Although interim analysis of patients that were confirmed with COVID-19 between May and August showed that molnupiravir reduced the risk of hospitalization and death by half compared to placebo, the same drug had much less effect, a 30% efficacy in reducing risk on those who were confirmed with COVID-19 between August and October. The reduced efficacy in the second half of the period when the delta mutation was dominant has been raising concern that molnupiravir may not be so effective against the delta variant. Also, a long-term safety concern has been raised on molnupiravir as a ribonucleoside analogue that enters the COVID-19 virus’s RNA. The concerns raised had deepened the authorities’ concerns over how to set the target patient group for the oral treatment. In other words, the number of patients that may be authorized to recieve molnupiravir may be partially restricted or limited. Pfizer had announced clinical trial results of Paxlovid demonstrating an 89% efficacy in high-risk patients. ALso, ongoing clinical trials indicate that there is a higher likelihood that a broader range of patients will be allowed to use Paxlovid. Pfizer is conducting trials on non-hospitalized patients at low risk of hospitalization or death (EPIC-SR) and as post-exposure prophylaxis on patients exposed to COVID-19 (EPIC-PEP). According to Pfizer’s announcement on the 14th, Paxlovid may reduce the risk of progression to moderate-to-severe disease by 70% in standard-risk patients such as healthy non-elderly adults or those who have risk factors but have received vaccinations. Based on such observations, the 242,000 courses of molnupiravir may not be used as much as expected and the 70,000 courses of Paxlovid may not be enough. Also, the price of Paxlovid may increase if molnupiravir has a lower-than-expected effect. Pfizer had raised the price of its COVID-19 vaccines in August for similar reasons. This is why we cannot rest assured with the 310,000 courses that we secured in advance.
- Company
- EMA designated Hanmi's HM15211 as ODD
- by Kim, Jin-Gu Dec 20, 2021 06:12am
- Hanmi Pharmaceutical's LAPSTriple Agonist, HM15211 announced on the 17th that it has been designated as ODD by the European Medicines Agency (EMA). According to Hanmi Pharmaceutical, EMA recently designated it as ODD for the treatment of primary sclerosing cholangitis, PSC. The LAPSTriple Agonist has previously been designated as ODD by the FDA. It was designated as a rare drug in March last year, and was once again designated as ODD in May this year. With this designation, LAPSTriple Agonist has become a new drug that has received a total of four rare drug designations, including three from the FDA and one from the EMA. Including this, Hanmi Pharmaceutical will hold a total of 18 ODD designated records (9 FDA cases, 6 EMA cases, and 3 MFDS cases) with 10 indications from 6 pipelines. At this point, it is the highest record among domestic pharmaceutical companies. LAPSTriple Agonist is a triple agonist that acts as a simultaneous activation of GLP-1 receptors, glucagon receptors, and GIP receptors. Based on multiple pharmacological effects, it is expected that excessive accumulation of bile acids in the liver will be reduced and liver inflammation and fibrosis will be suppressed to dramatically improve the quality of life of patients. Hanmi Pharmaceutical confirmed the effects of LAPSTriple Agonist on reducing bile acid accumulation and anti-inflammatory and anti-fibrotic effects. Primary sclerosing cholangitis is a chronic progressive bile identity liver disease caused by unknown intrahepatic biliary tract inflammation and fibrosis. The FDA and the EMA's designation of ODD is a system that supports the smooth development and permission of treatments for rare and intractable diseases or life-threatening diseases. In Europe, the cost of applying for permission will be reduced, and various benefits such as exclusive rights for 10 years will be granted when approving the first marketing permit among products of the same affiliate.
- Company
- Myung In’s Parkinson’s Tx demonstrates efficacy
- by Dec 20, 2021 06:12am
- A Parkinson’s disease treatment that Myung In Pharm has acquired an exclusive licensing agreement from an Israeli pharmaceutical company - 'P2B001 (Fixed-dose combination of pramipexole+rasagiline)’ – has demonstrated its safety and efficacy at a global Phase III clinical trial. According to the topline results announced by the Israeli pharmaceutical company Pharma Two B Ltd. (P2B), P2B001 successfully met its primary and key secondary endpoints and demonstrated statistically significant benefit over existing treatments. A total of 544 patients with early-stage Parkinson's disease in 70 centers in the US, Europe, and Canada were randomized to four treatment arms: P2B001 (pramipexole 0.6mg + rasagiline 0.75mg combination); pramipexole ER capsule (pramipexole 0.6 mg); rasagiline ER capsule (rasagiline 0.75mg); and the currently marketed pramipexole ER capsules titrated to an optimal dose for each individual. Patients in each treatment arm were administered their respective dose once a day for 12 weeks. The primary endpoint was the change in the total Unified Parkinson's Disease Rating Scale (UPDRS, defined as the sum of parts II and III) for P2B001 as compared to each of its components over 12 weeks. Results showed that P2B001 improved the total UPDRS score by 2.66 points compared to the pramipexole 0.6mg-treated arm (p=0.0018) and by 3.30 points compared to the rasagiline-treated arm (p=0.0001). Also, P2B001 showed significant improvement over its comparators in the secondary endpoint, Epworth Sleepiness Scale (ESS) score. From a safety prospect, P2B001 significantly reduced adverse events including sleepiness and orthostatic hypotension compared to the pramipexole ER capsule. The company explained that the trial results support the use of P2B001 as first-line treatment in patients with early-stage Parkinson's disease, once a day, without the need for titration. Hang Myung Lee, CEO/President of Myung In Pharm, said, “With the Phase III clinical trial results, we have now secured data that P2B001 has superior efficacy and a more significant safety profile over each of its individual components as well as the currently marketed pramipexole ER capsules. We believe that P2B001 could become an important new option when considering the long-term care plan that needs to be set for early-stage Parkinson's disease and the superior efficacy demonstrated in the trial.” P2B plans to submit a New Drug Application to the FDA next year. Myung In Pharm also plans to apply for marketing authorization of P2B001 to the Ministry of Food and Drug Safety in 2022 and release the drug in Korea in 2023. Myung In Pharm had acquired the exclusive license for the commercialization of P2B001 in Korea through an equity investment in P2B in November this year.
- Company
- Expectations rise for Lilly’s Alzheimer drug
- by Eo, Yun-Ho Dec 20, 2021 06:11am
- Expectations have been rising for the commercialization of Lilly’s new drug candidate for Alzheimer’s. On the 15th (local time), Eli Lilly announced that it will complete filing for approval of its new Alzheimer’s candidate ‘donanemab’ within the first quarter of 2022. The news was announced at an investor meeting while introducing plans for five new drugs that will be launched within the next two years. Lilly had previously said that an application for approval of donanemab would be made sometime next year. if Lilly’s donanemab is approved, the addition of donanemab to the market following Biogen’s accelerated approval of Aduhelm in June is expected to intensify competition. Although the information available on donanemab is limited, a head-to-head study against Aduhelm is ongoing, and initial data from the study is expected to roll out in the second half of next year. Based on the initial data from a Phase II trial announced earlier this year, the FDA granted Breakthrough Therapy designation for donanemab in June. Results of Lilly’s Phase II TRAILBLAZER-ALZ trial on donanemab is a monoclonal antibody that targets a modified form of beta-amyloid called N3pG that was released in July demonstrated that the reduced beta-amyloid deposits slowed the decline of cognitive function in Alzheimer patients. Donanemab Patients with early symptoms of Alzheimer’s who were administered donanemab in the trial showed a rapid reduction in amyloid plaque at 24 weeks and showed the most rapid amyloid plaque removal in patients who had the most severe plaque burden at baseline. At the meeting, Lilly also announced its release plans for its antidiabetic tirzepatide, mantle cell lymphoma treatment pirtobrutinib, ulcerative colitis treatment mirikizumab, and atopic dermatitis treatment lebrikizumab.
- Policy
- Korea tightens social distancing measures again
- by Kim, Jung-Ju Dec 20, 2021 06:11am
- The surge in COVID-19 cases in Korea has led the government to once again tighten the reins on social distancing while focusing on encouraging booster shot vaccinations. Private gatherings will be once again limited to no more than four people in all areas regardless of region, and a ‘vaccine pass’ that differs the level of restrictions imposed based on vaccination status will be applied. On the 16th, the COVID-19 Central Disaster and Safety Countermeasures Headquarters (Prime Minister Kim Boo-kyum) held a meeting with central ministries and 17 regional governments at the video conference room in the video conference room of the Central Government Complex in Seoul to discuss strengthening the social distancing measures by expanding booster vaccination and expanding medical capacity to establish a continuous basis for the phased recovery to daily life. Currently, Korea’s COVID-19 urgency assessment showed Korea to be at ‘very-high’ risk in all regions - nationwide, metropolitan, and non-metropolitan areas – for two consecutive weeks since last week. The intensive care bed operation rate reached 81.6% nationwide, 86.4% in metropolitan areas, and 72.9% in non-metropolitan areas. In particular, the surge in intensive care operation rate in non-metropolitan areas with relatively low medical response capacity was deemed a major risk factor that could lead to a nationwide medical collapse. With the number of non-vaccinated people over the age of 60 that have a high probability of infection still nearing 910,000 (6.9%) and the number of cases of severe and critical COVID-19 and deaths similar in the vaccinated and non-vaccinated groups, it is necessary to protect the elderly who are not vaccinated through vaccination. With booster vaccination rates nearing 87%, the rate of mass infection is falling in long-term care hospitals and facilities, but the booster vaccination rate in those 60 years or older is still low at 46.4%. Therefore, the government decided to implement strengthened social distancing measures to block further transmission of COVD-19 in non-vaccinated people that account for half of the severe and critical COVID-19 patients and deaths and minimize individual contact to ultimately remove the overall risk factors remaining in society. The strengthened social distancing measures will be implemented for 16 days from the 18th of this month to January 2nd. The authorities readjusted the number of people allowed for private gatherings to reduce contact between individuals in consideration of the seasonal factor and the increased risk of transmission from year-end and new year gatherings and other indoor activities. Therefore, the number of people allowed for social gatherings that were 6 in metropolitan and 8 in non-metropolitan areas was reduced to 4 regardless of an individual’s vaccination status. However, the existing exclusion that was applied to immediate families in cohabitation, individuals in need of care (children, elderly, and the disabled), etc. remain effective. Also, under the changed measures, non-vaccinated individuals may now only use restaurants and cafes alone. Also, taking into account the increased risk of COVID-19 transmission if activities extend to late-night hours and are associated with alcohol consumption and non-mask use, the authorities restricted the operation hours of multi-use facilities to 9 or 10 p.m. for the next 2 weeks. Operation hours for Group 1 facilities (entertainment facilities) and Group 2 facilities (restaurants, cafes, singing rooms, public baths, indoor sports facilities) will be restricted to 9:00 p.m., and the hours for Group 3 and other facilities (movie theaters, performance centers, game arcade, multi-rooms, casinos, internet café(PC rooms), private academies, massage salons, party rooms) will be restricted to 10 p.m. Sizes of events and assemblies will also be restricted. Currently, events and assemblies with less than 100 participants are allowed regardless of vaccination status, and up to 499 vaccinated individuals may gather for events, and assemblies with over 100 participants are allowed. However, the strengthened measures restrict the number of participants to 50 regardless of vaccination status, and up to 299 vaccinated individuals may gather for events and assemblies with over 50 participants. Although events with over 300 participants (limited to those held in non-regular performance centers, sports competitions, festivals) are prohibited in principle, they may be held as an exception with prior approval from relevant ministries. For the next two weeks, all events other than essential events will be disapproved in consideration of the severe COVID-19 situation. Also, official duties and events related to essential corporate activities that were exempted from being applied the vaccine pass will be subject to the same restrictions if there are more than 50 participants (no increase in participants allowed), and exhibitions, expos, and international conferences that had been managed with a separate regulation is also applied the vaccine pass if there are more than 50 participants (no increase in participants allowed).
- Company
- Ildong signed for Nexium worth ₩50 billion
- by Dec 20, 2021 06:11am
- AstraZeneca Korea announced on the 14th that it has signed a partnership contract with Ildong for gastroesophageal reflux disease treatment "Nexium (Esomeprazole)" and type 2 diabetes treatment "Qtern (Dapagliflozin/Saxagliptin Monohydrate)." Through this, Ildong Pharmaceutical will jointly sell Nexium and Qtern with AstraZeneca Korea from January 1 next year. In 2014, the two companies promoted Onglyza and Komblyze XR (Metformin HCl/Saxaglipin Monohydrate). Ildong Pharmaceutical has succeeded in marketing H2 receptor antagonists, PPI drugs, and functional dyspepsia treatments. Ildong Pharmaceutical plans to grow Nexium into an item with annual sales of more than 50 billion won in the future. Last year, Nexium's domestic sales were estimated at about 49.4 billion won. Nexium was jointly sold by Daewoong Pharmaceutical, and the contract ends on December 31. Daewoong Pharmaceutical plans to focus on selling its own P-CAB-based gastroesophageal reflux disease treatments Fexuprazan and Nexium. Kim Sang-pyo, CEO of AstraZeneca Korea, said, "We are happy that the two companies, which have been maximizing each other's strengths in the diabetes treatment field for the past eight years, are seeking opportunities for a new leap forward in the digestive field." He said, "We hope to provide differentiated treatment benefits of 'Nexium' and 'Qtern' to more medical staff and patients." Yoon Woong-seop, vice chairman of Ildong Pharmaceutical, said, "We are looking forward to strengthening our partnership with AstraZeneca Korea through Nexium and Qtern following Onglyza and Kombiglyze XR." He said, "We plan to do our best not only for the health of patients but also for the smooth medical activities of medical staff, but also to create synergy between the two companies and expand market performance."
- Company
- New depression drug Spravato lands in the 'Big 5' Hospitals
- by Eo, Yun-Ho Dec 16, 2021 05:52am
- Janssen’s new drug for depression, ‘Spravato,’ can now be prescribed at general hospitals in Korea. According to industry sources, Spravato (esketamine) that is used in combination with an oral antidepressant, has passed the review of drug committees (DC) of 80 medical institutions in the nation including the 'Big-5' general hospitals - Samsung Medical Center (SMC), Seoul National University Hospital (SNUH), Seoul St. Mary’s Hospital, and Severance Hospital - as well as the Kyung Hee University Medical Center, Kyungpook National University Hospital, Inje University Paik Hospital, Seoul National University Bundang Hospital, Chung-Ang University Hospital, Jeju National University Hospital, Inje University Haeundae Paik Hospital. Spravato, which was approved in June last year in Korea, was the first-ever prescription nasal spray with a new mechanism of action that was introduced in the field of treatment-resistant depression (TRD) and the first in 30 years introduced in the field of major depressive disorder. Spravato’s esketamine modulates the glutamate receptor called an N-methyl D-aspartate (NMDA) receptor in the brain and restores synaptic function and increases neurotrophic signaling to improve depression symptoms. Last year, the drug added an indication for the treatment of major depressive disorder with suicidal thoughts or actions. The approval of the depression with suicidal ideation indication was based on results of the global Phase III ASPIRE I and ASPIRE II study. In both ASPIRE I and ASPIRE II, Spravato met the primary endpoint as defined as the reduction in depressive symptoms from baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) at 24 hours after the first dose when taken in conjunction with standard of care therapy (including oral antidepressants and hospitalization). Efficacy for the initial indication of treatment-resistant depression was demonstrated through a Phase 3 clinical trial consisting of short- and long-term trials that were conducted on 1,700 adult patients with treatment-resistant depression. In the short-term clinical trial on patients aged 18 to 65 years with treatment-resistant depression, the MADRS score of patients who were administered Spravato in combination with oral antidepressants was lowered by 19.8 points during the 4-week treatment period. Patients who were administered a placebo showed a 15.8 point reduction in the MADRS score, demonstrating a statistically significant improvement in symptoms of patients who used Spravato with an oral antidepressant. In the long-term trial, the probability of recurrent depressive symptoms was 51% percent lower in the Spravato +oral antidepressant-treated group that achieved stable remission than that of the placebo+oral antidepressant-treated group. Jong-woo Paik, Professor of Mental Health and Medicine at Kyunghee University, said, “Unlike other antidepressants that take several days for symptoms to improve after intake, Spravato showed immediate improvement in depressive symptoms. Such a characteristic is particularly effective in treating and managing patients in emergencies such as those who had attempted suicides.”
- Policy
- Jeil's JP-1366 has been approved for phase 3 in Korea
- by Lee, Tak-Sun Dec 16, 2021 05:51am
- Jeil's new drug candidate JP-1366 for GERD has been approved for phase 3 clinical trials and is speeding up commercialization. Currently, sales of HK inno.N's P-CAB-based new drug K-Cab are high in Korea. On the 14th, the MFDS approved a phase 3 clinical trial plan for JP-1366 applied by Onconic Theapeutics, a subsidiary of Jeil Pharmaceutical. This clinical trial is a randomized, double-blind, parallel design, activity contrast, non-isomeric, multi-organ phase 3 clinical trial that compares and evaluates the efficacy and safety of JP-136620 mg or Esomeprazole 40 mg administration in erosive esophagitis patients. JP-1366 is a treatment for gastroesophageal reflux disease in the P-CAB mechanism and is expected to be a drug that improves the limitations of existing PPI formulations. It is more effective and lasts longer than PPI. It was selected as a high-tech medical technology development project by the MOHW in 2017 and received about 2 billion won in research funds, and is being fostered as a global new drug in public-private cooperation. Clinical trials are being conducted not only in Korea but also in Europe. Onconic Theapeutics is a subsidiary of the new drug development established in May last year with 100% investment in Jeil Pharmaceutical. Currently, Jeill is developing new drug candidates such as JP-1366, a treatment for GERD, and "JPI-547," a next-generation dual-target anticancer drug. The company aims to be listed in 2024. The P-CAB-based new drug was developed by HK inno.N as K-cab for the first time in Korea in 2018. K-cab has become a treatment for GERD as soon as it is released in 2019. Sales are expected to exceed 100 billion won this year. Accordingly, not only Jeil but also other domestic companies such as Daewoong Pharmaceutical are spurring the development of new P-CAB drugs. Fexuprazan, which is being developed by Daewoong Pharmaceutical, is known to have completed clinical trials in Korea and is undergoing approval procedures.
